Cavalcante Fabiano, Treurniet Kilian M, Kappelhof Manon, Kaesmacher Johannes, Lingsma Hester F, Saver Jeffrey L, Gralla Jan, Fischer Urs, Majoie Charles B, Roos Yvo B W E M
Department of Radiology and Nuclear Medicine (F.C., K.M.T., M.K., C.B.M.), Amsterdam University Medical Centers, University of Amsterdam, Amsterdam Neuroscience, the Netherlands.
Department of Radiology, Haaglanden Medical Center, The Hague, the Netherlands (K.M.T.).
Stroke. 2025 Feb;56(2):543-552. doi: 10.1161/STROKEAHA.124.048024. Epub 2025 Jan 2.
Noninferiority trials aim to prove that the efficacy, defined in terms of a key clinical outcome, of a new treatment is not meaningfully worse than that of an established active control. Noninferiority trials are important when other aspects of care can be improved, such as convenience, toxicity, costs, and safety (nonefficacy benefits). While the motivation for a noninferiority trial is straightforward, the design, execution, and interpretation of these trials is not a trivial task. Several safeguards that protect superiority trials from incorrect conclusions do not apply or even work in reverse for noninferiority trials. This review aims to provide stroke clinicians and researchers with a general overview of noninferiority trials and a deeper understanding of 10 pitfalls they should consider when designing and interpreting such trials.
非劣效性试验旨在证明,就关键临床结局而言,新治疗方法的疗效并不显著低于既定的活性对照。当护理的其他方面(如便利性、毒性、成本和安全性(非疗效益处))可以得到改善时,非劣效性试验就很重要。虽然非劣效性试验的动机很直接,但这些试验的设计、实施和解释并非易事。一些保护优效性试验避免得出错误结论的保障措施并不适用于非劣效性试验,甚至在非劣效性试验中会起到相反的作用。本综述旨在为中风临床医生和研究人员提供非劣效性试验的总体概述,并更深入地了解他们在设计和解释此类试验时应考虑的10个陷阱。